Hope for MS sufferers as stem cell trial shows astonishing results

Support us and go ad-free

Doctors in Canada have treated 24 patients with primary progessive MS (multiple sclerosis) using a highly risky and experimental stem cell treatment. Follow ups over up to 13 years following treatment showed that it put the brakes on progression of the disease, which would usually have caused severe disability in that time.

The treatment involves complete destruction of a patient’s immune system before rebooting it, using the patient’s own stem cells. This is a very risky procedure and one of the 24 patients actually died during the treatment, from severe liver damage and a bacterial blood infection.

MS is an autoimmune disease of the central nervous system, affecting around 100,000 people in the UK. The body’s own immune defences malfunction, causing destruction of myelin – a protein that coats and insulates nerve fibres, like the plastic around a copper wire. In primary progressive MS, the disease gradually gets worse over time, with the exposed nerve fibres short circuiting, causing a range of symptoms including problems with vision and balance, dizziness, fatigue, and stiffness or spasms.

The clinical trial, carried out at the University of Ottowa, removed the patients’ own bone marrow stem cells by administering a drug that causes them to move into the blood stream. These cells were removed – effectively extracting the main part of the patient’s immune system – and then purified to eliminate those cells that cause MS. Once the patient’s remaining immune system is completely destroyed by chemotherapy, the normal stem cells are introduced back into the patient’s body. There, they slowly rebuild the immune system with cells that are not going to attack their myelin. The researchers described this as a “reboot”.

The study has been broadly applauded by scientists and MS charities and support groups. Siddharthan Chandran, Professor of Neurology at the Medical Research Council Centre for Regenerative Medicine, University of Edinburgh said:

This is an important and carefully conducted proof of concept study that demonstrates that powerful chemotherapy based treatment for a selected subset of MS patients with very aggressive disease is effective in preventing further disabling relapses and, in a proportion, appears to render them effectively disease free.

Dr Stephen Minger, a stem cell biologist and independent consultant added:

Read on...

Support us and go ad-free

…the clinical results are truly impressive, in some cases close to being curative.

Both scientists cautioned that this is still an early study and although there has been long-term follow up, time will tell if the patients continue to be well throughout their lives. There is also the risk factor in the treatment, which is highly radical and has significant safety concerns. It may, therefore, only be suitable for patients with primary progressive MS who are expected to become more ill, more quickly. Professor Chandran added that there is a need to develop tests that can predict patient outcomes in this way before choosing a radical and experimental treatment.

Dr Emma Gray, Head of Clinical Trials at the MS Society said:

This type of stem cell transplantation is a rapidly evolving area of MS research that holds a lot of promise for people with certain types of MS.

In this latest trial patients were monitored post treatment for a longer period than previous studies, providing valuable information about the long term safety and effectiveness of HSCT [Haematopoietic Stem Cell Transplantation] as well as who might benefit.

This treatment does offer hope, but it’s also an aggressive procedure that comes with substantial risks and requires specialist aftercare. If anyone is considering HSCT we’d recommend they speak to their neurologist.

According to The Guardian, this isn’t the first clinical trial of stem cell transplantation for MS, but all previous trials found the patients relapsed within a couple of years. The new trial takes a far more aggressive approach, which while successful, is also more risky.

It will take some time for this treatment to become available more widely, but it seems safe to be tentatively optimistic that this may offer hope to the most unwell MS patients within a few years.

Get Involved

Feature image via Pixabay

Support us and go ad-free

We need your help to keep speaking the truth

Every story that you have come to us with; each injustice you have asked us to investigate; every campaign we have fought; each of your unheard voices we amplified; we do this for you. We are making a difference on your behalf.

Our fight is your fight. You’ve supported our collective struggle every time you gave us a like; and every time you shared our work across social media. Now we need you to support us with a monthly donation.

We have published nearly 2,000 articles and over 50 films in 2021. And we want to do this and more in 2022 but we don’t have enough money to go on at this pace. So, if you value our work and want us to continue then please join us and be part of The Canary family.

In return, you get:

* Advert free reading experience
* Quarterly group video call with the Editor-in-Chief
* Behind the scenes monthly e-newsletter
* 20% discount in our shop

Almost all of our spending goes to the people who make The Canary’s content. So your contribution directly supports our writers and enables us to continue to do what we do: speaking truth, powered by you. We have weathered many attempts to shut us down and silence our vital opposition to an increasingly fascist government and right-wing mainstream media.

With your help we can continue:

* Holding political and state power to account
* Advocating for the people the system marginalises
* Being a media outlet that upholds the highest standards
* Campaigning on the issues others won’t
* Putting your lives central to everything we do

We are a drop of truth in an ocean of deceit. But we can’t do this without your support. So please, can you help us continue the fight?

The Canary Support us

Comments are closed